Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Puma Biotechnology ( (PBYI) ) is now available.
On June 19, 2025, Puma Biotechnology‘s Board of Directors approved amendments to the company’s Fourth Amended and Restated Bylaws to align with updates in Delaware law. These changes are expected to streamline governance and ensure compliance with legal standards, potentially impacting the company’s operational efficiency and stakeholder relations.
The most recent analyst rating on (PBYI) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Puma Biotechnology stock, see the PBYI Stock Forecast page.
Spark’s Take on PBYI Stock
According to Spark, TipRanks’ AI Analyst, PBYI is a Neutral.
Puma Biotechnology’s overall stock score reflects its financial improvements, technical momentum, and attractive valuation. However, the company’s challenges with revenue consistency and leverage, combined with mixed earnings call insights, temper the outlook. Long-term prospects may depend on successful execution of strategic initiatives and stabilization of revenue.
To see Spark’s full report on PBYI stock, click here.
More about Puma Biotechnology
Puma Biotechnology, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative products for the treatment of cancer. The company is known for its efforts in creating targeted cancer therapies, aiming to improve patient outcomes and address unmet medical needs in oncology.
Average Trading Volume: 345,996
Technical Sentiment Signal: Hold
Current Market Cap: $158.6M
For an in-depth examination of PBYI stock, go to TipRanks’ Overview page.